GT Biopharma Inc. (GTBP)
NASDAQ: GTBP
· Real-Time Price · USD
1.49
0.15 (11.19%)
At close: Aug 18, 2025, 10:56 AM
GT Biopharma Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -1.93M | -3.76M | -3.6M | -3.91M | -3.09M | -3.17M | -3.12M | -3.62M | -3.67M | -5.78M | -7.02M | -3.01M | -5.44M | -18.18M | -5.95M | -4.38M | -29M |
Interest Income | 32K | 59K | 96K | 105K | 142K | 180K | 216K | 220K | 164K | 141K | 107K | 36K | 8K | 6K | 32K | n/a | n/a |
Pretax Income | -776K | -3.77M | -3.41M | -3.71M | -2.27M | -2.96M | -2.42M | -1.99M | -227K | -5.58M | -6.88M | -2.98M | -5.44M | -18.02M | -5.45M | -4.86M | -29.68M |
Net Income | -776K | -3.77M | -3.41M | -3.71M | -2.27M | -2.96M | -2.42M | -1.99M | -227K | -5.58M | -6.88M | -2.98M | -5.44M | -18.02M | -5.45M | -4.86M | -29.68M |
Selling & General & Admin | 833K | 1.83M | 2.3M | 2.12M | 2.31M | 1.81M | 1.76M | 1.53M | 2.02M | 2.94M | 4.28M | 1.88M | 3.35M | 11.87M | 4.95M | 3.74M | 27.36M |
Research & Development | 1.1M | 1.93M | 1.31M | 1.78M | 777K | 1.36M | 1.36M | 2.1M | 1.65M | 2.84M | 2.74M | 1.14M | 2.09M | 6.3M | 1.01M | 639K | 1.64M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 1.93M | 3.76M | 3.6M | 3.91M | 3.09M | 3.17M | 3.12M | 3.62M | 3.67M | 5.78M | 7.02M | 3.01M | 5.44M | 18.18M | 5.95M | 4.38M | 29M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1K | 212K | 8K | n/a | n/a | n/a | 22K | n/a | n/a | 696K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | 285K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 1.93M | 3.76M | 3.6M | 3.91M | 3.09M | 3.17M | 3.12M | 3.62M | 3.67M | 5.78M | 7.02M | 3.01M | 5.44M | 18.18M | 5.95M | 4.38M | 29M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 2.35M | 1.9M | 2.23M | 1.71M | 1.38M | 1.38M | 1.37M | 1.34M | 1.08M | 1.18M | 8.65M | 1.04M | 1.08M | 8.65M | 1.05M | 1.12M | 541.33K |
Shares Outstanding (Diluted) | 2.35M | 1.9M | 2.23M | 1.71M | 1.38M | 1.38M | 1.37M | 1.34M | 1.08M | 1.18M | 8.65M | 1.04M | 1.08M | 8.65M | 1.05M | 1.12M | 541.33K |
EPS (Basic) | -0.33 | -1.99 | -1.53 | -2.17 | -1.64 | -2.15 | -1.77 | -1.49 | -0.21 | -4.72 | -0.77 | -2.86 | -5.02 | -2.08 | -5.21 | -4.35 | -54.9 |
EPS (Diluted) | -0.33 | -1.99 | -1.53 | -2.17 | -1.64 | -2.15 | -1.77 | -1.49 | -0.21 | -4.72 | -0.77 | -2.86 | -5.02 | -2.08 | -5.21 | -4.35 | -54.9 |
EBITDA | -1.93M | -3.77M | -3.41M | -3.71M | 825K | -2.96M | -2.42M | -1.99M | -15K | -5.58M | -6.88M | -2.98M | -5.44M | -18M | -5.45M | -4.86M | -28.98M |
EBIT | -1.93M | -3.77M | -3.41M | -3.71M | -2.27M | -2.96M | -2.42M | -1.99M | -15K | -5.58M | -6.88M | -2.98M | -5.44M | -18M | -5.45M | -4.86M | -28.98M |
Depreciation & Amortization | n/a | n/a | n/a | n/a | 3.09M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |